ArticleBritish journal of cancer2026
Delving into tRNA-derived small RNAs in multiple myeloma: elevated 3'U-tRF
Konstantinos Soureas, Panagiotis Malandrakis, Maria-Alexandra Papadimitriou, Ioannis Ntanasis-Stathopoulos, Katerina-Marina Pilala, Christine-Ivy Liacos, Maria Gavriatopoulou, Efstathios Kastritis, Meletios-Athanasios Dimopoulos, Andreas Scorilas and 2 more
Abstract read
In one paragraphArticle in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Konstantinos SoureasDepartment of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.
Panagiotis MalandrakisDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece.
Maria-Alexandra PapadimitriouDepartment of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.
Ioannis Ntanasis-StathopoulosDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece.ORCID http://orcid.org/0000-0002-6328-9783 Katerina-Marina PilalaDepartment of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.
Christine-Ivy LiacosDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece.
Maria GavriatopoulouDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece.
Efstathios KastritisDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece.
Meletios-Athanasios DimopoulosDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece.ORCID http://orcid.org/0000-0001-8990-3254 Evangelos Terpos *Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece. eterpos@med.uoa.gr.ORCID http://orcid.org/0000-0001-5133-1422 Margaritis Avgeris *Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. mavgeris@med.uoa.gr.ORCID http://orcid.org/0000-0002-2135-9886 Funding
European Commission (EC) 101097094
6 · The paper itselfAbstract
backgroundMultiple myeloma (MM) is an incurable malignancy, marked by treatment resistance and frequent relapses, posing ongoing challenges to patients' long-term management. Herein, we have examined tRNA-derived small RNA fragments (3'U-tRFs), generated from precursor tRNAs, to identify MM-related 3'U-tRFs in ameliorating MM precision prognostics.
methods3'U-tRF profiles were generated by small RNA-seq data. Target prediction and gene ontology analysis were assessed by tRFtarget and DAVID databases, respectively. CD138 + 3'U-tRF
resultsSmall RNA-seq data analysis highlighted the significantly increased 3'U-tRF
conclusionsOur study indicate the elevated 3'U-tRF
Indexed as
Multiple MyelomaRNA, TransferBiomarkers, TumorFemaleHumansMalePrognosisBiomarkers, TumorRNA, Transfer
Identifiers
PMID42082650
PMCPMC13373171
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390